Orris

M pharm 1 sem Advance pharmacology unit 1 all expected , deep , depth ,multiple choice questions with answers

Reading File
Finding Sources
Searching the Web

M Pharm 1st semester advanced pharmacology unit 1 syllabus topics 2024

Finding Sources
Searching the Web

M Pharm advanced pharmacology unit 1 syllabus pharmacodynamics receptor pharmacokinetics molecular

Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
I now have all the content needed. Let me compile the comprehensive MCQ bank.
Here is the complete, deep, exam-ready MCQ bank for M.Pharm 1st Semester - Advanced Pharmacology Unit 1. This covers all major topics: Pharmacokinetics (ADME, compartment models, protein binding, clearance, half-life) and Pharmacodynamics (receptors, signal transduction, dose-response, agonists/antagonists).

M.Pharm Sem 1 - Advanced Pharmacology Unit 1

Comprehensive MCQ Bank (80+ Questions with Answers & Explanations)

SECTION A: PHARMACOKINETICS - ABSORPTION

Q1. The process by which a drug moves from its site of administration into the systemic circulation is called:
  • A) Distribution
  • B) Absorption
  • C) Biotransformation
  • D) Elimination
Answer: B) Absorption Explanation: Absorption is the transfer of drug from the site of administration to the bloodstream. All other processes occur after the drug enters circulation.
Q2. Which of the following mechanisms of drug absorption requires a carrier protein and moves drug against a concentration gradient?
  • A) Passive diffusion
  • B) Facilitated diffusion
  • C) Active transport
  • D) Endocytosis
Answer: C) Active transport Explanation: Active transport requires energy (ATP), uses a specific carrier, and can move drug against the concentration gradient. Facilitated diffusion uses a carrier but moves drug down the gradient and requires no energy.
Q3. The Henderson-Hasselbalch equation for a weak acid is:
  • A) pH = pKa + log [ionized/unionized]
  • B) pH = pKa + log [unionized/ionized]
  • C) pH = pKa - log [A-/HA]
  • D) pH = pKa + log [HA/A-]
Answer: A) pH = pKa + log [ionized/unionized] Explanation: For a weak acid: pH = pKa + log [A-]/[HA] = pKa + log [ionized form]/[unionized form]. At pH = pKa, 50% of the drug is ionized.
Q4. A weakly acidic drug (pKa 4.4) is in the stomach (pH 1.4). What fraction is unionized?
  • A) 50%
  • B) 99.9%
  • C) 1%
  • D) 0.1%
Answer: B) 99.9% Explanation: pH - pKa = 1.4 - 4.4 = -3. Log [A-]/[HA] = -3, so [A-]/[HA] = 0.001/1 = 1:1000. 99.9% is unionized (uncharged = lipid soluble = absorbed well from stomach).
Q5. P-glycoprotein (P-gp) is an efflux transporter. Its clinical significance includes:
  • A) Increasing bioavailability of all drugs
  • B) Causing multi-drug resistance and reducing bioavailability
  • C) Enhancing absorption of hydrophilic drugs
  • D) Facilitating first-pass metabolism
Answer: B) Causing multi-drug resistance and reducing bioavailability Explanation: P-gp is a transmembrane efflux transporter expressed in intestine, liver, kidneys, BBB, and tumor cells. It pumps drugs back into the gut lumen, reducing absorption, and is a key mechanism of MDR in cancer (Lippincott Pharmacology).
Q6. First-pass metabolism is MOST significant for which route of administration?
  • A) Intravenous
  • B) Sublingual
  • C) Oral
  • D) Inhalation
Answer: C) Oral Explanation: Orally administered drugs absorbed from the GI tract enter the portal circulation and pass through the liver before reaching systemic circulation. Drugs with high hepatic extraction (e.g., lidocaine, morphine, propranolol) undergo extensive first-pass metabolism, greatly reducing bioavailability.
Q7. Bioavailability (F) of an oral drug is calculated as:
  • A) AUC(oral) / AUC(IV) × 100
  • B) AUC(IV) / AUC(oral) × 100
  • C) Cmax(oral) / Dose
  • D) T1/2 × Clearance
Answer: A) AUC(oral) / AUC(oral) × 100 (Corrected: AUC(oral) / AUC(IV) × 100) Answer: A) F = [AUC(oral) / AUC(IV)] × 100% Explanation: Absolute bioavailability compares the AUC after oral dosing to that after IV dosing (which by definition has 100% bioavailability). It reflects the fraction of the administered dose that reaches systemic circulation unchanged.
Q8. Which of the following factors does NOT affect drug absorption from the GI tract?
  • A) Particle size of the drug
  • B) pKa of the drug
  • C) Plasma protein binding
  • D) GI motility
Answer: C) Plasma protein binding Explanation: Plasma protein binding affects distribution and elimination, not absorption from the GI tract. Particle size (affects dissolution), pKa (affects ionization state), and GI motility (affects contact time) all directly influence absorption.

SECTION B: PHARMACOKINETICS - DISTRIBUTION

Q9. The volume of distribution (Vd) is defined as:
  • A) The actual fluid volume in the body
  • B) The apparent volume into which a drug distributes assuming it is at the same concentration as plasma
  • C) The total body water (42 L)
  • D) The volume of blood in the body
Answer: B) The apparent volume into which a drug distributes assuming it is at the same concentration as plasma Explanation: Vd = Amount of drug in body / Plasma drug concentration. It is a theoretical volume, not a real anatomical compartment. A large Vd (e.g., >100 L) means extensive tissue distribution; a small Vd (~3-5 L) suggests confinement to plasma.
Q10. A drug with a Vd of 500 L suggests:
  • A) The drug is highly protein bound in plasma
  • B) The drug is confined to plasma
  • C) The drug is extensively distributed into tissues
  • D) The drug is renally excreted unchanged
Answer: C) The drug is extensively distributed into tissues Explanation: Normal blood volume is ~5 L and total body water is ~42 L. A Vd of 500 L cannot correspond to any real body compartment - it means the drug is avidly bound to tissue proteins or distributed into adipose tissue (e.g., chloroquine Vd ~200-800 L/kg).
Q11. Which of the following drugs would have the SMALLEST volume of distribution?
  • A) Chloroquine
  • B) Digoxin
  • C) Heparin
  • D) Amiodarone
Answer: C) Heparin Explanation: Heparin is a large, polar, charged molecule that cannot cross cell membranes and remains in the vascular compartment (Vd ~0.05-0.1 L/kg). Chloroquine, digoxin, and amiodarone all have very large Vd due to extensive tissue binding.
Q12. The blood-brain barrier (BBB) allows entry of drugs that are:
  • A) Ionized and hydrophilic
  • B) Large molecular weight proteins
  • C) Unionized and lipophilic
  • D) Highly protein bound
Answer: C) Unionized and lipophilic Explanation: The BBB consists of tight junctions between endothelial cells and lacks fenestrations. Only small, lipophilic, unionized molecules can cross by passive diffusion. Large or charged molecules cannot enter the CNS by passive means.
Q13. Drug displacement from plasma protein binding sites is clinically important because:
  • A) It always reduces drug effect
  • B) The free fraction increases, potentially increasing pharmacological effect and toxicity
  • C) It permanently increases total drug concentration
  • D) It increases half-life
Answer: B) The free fraction increases, potentially increasing pharmacological effect and toxicity Explanation: Only free (unbound) drug is pharmacologically active. Displacement from albumin (e.g., warfarin displaced by aspirin) transiently raises free drug levels, increasing both effect and risk of toxicity. This is particularly significant for drugs with narrow therapeutic indices.
Q14. Which plasma protein primarily binds acidic drugs (e.g., warfarin, diazepam)?
  • A) Alpha-1 acid glycoprotein (AAG)
  • B) Albumin
  • C) Beta-globulin
  • D) Fibrinogen
Answer: B) Albumin Explanation: Albumin (MW ~69,000 Da) primarily binds acidic drugs and some neutral drugs. Alpha-1 acid glycoprotein (AAG/orosomucoid) primarily binds basic drugs (e.g., lidocaine, propranolol, imipramine).

SECTION C: PHARMACOKINETICS - METABOLISM (BIOTRANSFORMATION)

Q15. Phase I metabolic reactions primarily involve:
  • A) Glucuronidation, sulfation, and acetylation
  • B) Oxidation, reduction, and hydrolysis
  • C) Conjugation with glutathione
  • D) Methylation and glycine conjugation
Answer: B) Oxidation, reduction, and hydrolysis Explanation: Phase I reactions introduce or unmask a functional group (-OH, -NH2, -COOH) through oxidation, reduction, or hydrolysis. They usually produce a more polar, less active metabolite but sometimes produce toxic/active metabolites (e.g., codeine → morphine).
Q16. The cytochrome P450 (CYP) enzyme system is located primarily in:
  • A) Kidneys and lungs
  • B) Endoplasmic reticulum of hepatocytes
  • C) Plasma membrane of enterocytes
  • D) Mitochondria of all cells
Answer: B) Endoplasmic reticulum of hepatocytes Explanation: CYP enzymes are concentrated in the smooth endoplasmic reticulum (microsomes) of hepatocytes. They are also present in intestinal enterocytes (CYP3A4), lungs, adrenal gland, and other tissues, but the liver is the primary site.
Q17. Induction of CYP3A4 by rifampicin leads to:
  • A) Increased plasma levels of co-administered drugs metabolized by CYP3A4
  • B) Decreased metabolism and toxicity
  • C) Decreased plasma levels of CYP3A4 substrates due to faster metabolism
  • D) Irreversible inhibition of the enzyme
Answer: C) Decreased plasma levels of CYP3A4 substrates due to faster metabolism Explanation: Enzyme inducers (rifampicin, carbamazepine, phenobarbital, St. John's Wort) increase CYP synthesis, leading to faster metabolism of substrates (e.g., oral contraceptives, warfarin, HIV protease inhibitors) and reduced therapeutic efficacy.
Q18. Which CYP isoform is responsible for metabolism of the LARGEST number of clinical drugs (~50%)?
  • A) CYP1A2
  • B) CYP2D6
  • C) CYP2C9
  • D) CYP3A4
Answer: D) CYP3A4 Explanation: CYP3A4 metabolizes approximately 50% of all clinically used drugs. It is the most abundant hepatic CYP and is also highly expressed in intestinal enterocytes. CYP2D6 metabolizes ~25% despite being polymorphic. CYP2C9 handles ~15%.
Q19. An individual who is a "poor metabolizer" for CYP2D6 would show which outcome with codeine?
  • A) Rapid conversion to morphine, risk of toxicity
  • B) No conversion to morphine, poor analgesia
  • C) Enhanced prodrug activation
  • D) Normal analgesic response
Answer: B) No conversion to morphine, poor analgesia Explanation: Codeine is a prodrug requiring CYP2D6 for O-demethylation to morphine (active). Poor metabolizers lack functional CYP2D6 - they cannot convert codeine to morphine and get little/no analgesia. Ultra-rapid metabolizers produce excess morphine and may die of respiratory depression.
Q20. Phase II reactions (conjugation) typically result in:
  • A) More lipophilic, active metabolites
  • B) More water-soluble, polar metabolites facilitating excretion
  • C) Toxic reactive intermediates
  • D) Reduced molecular weight
Answer: B) More water-soluble, polar metabolites facilitating excretion Explanation: Phase II reactions conjugate the drug (or Phase I metabolite) with an endogenous molecule (glucuronic acid, sulfate, glutathione, glycine, acetyl group, methyl group). The products are larger, more polar, and more water-soluble, facilitating biliary or renal excretion.
Q21. The "first-pass effect" can be bypassed by all of the following routes EXCEPT:
  • A) Sublingual
  • B) Transdermal
  • C) Rectal (upper rectum)
  • D) Intravenous
Answer: C) Rectal (upper rectum) Explanation: The upper rectal veins drain into the portal circulation, so drugs absorbed from the upper rectum DO undergo first-pass metabolism. The lower rectum drains into the inferior vena cava, bypassing the liver. Sublingual, transdermal, and IV routes all bypass hepatic first-pass.
Q22. Acetylation polymorphism (NAT2 enzyme) is clinically relevant for which drug?
  • A) Codeine
  • B) Isoniazid
  • C) Warfarin
  • D) Metoprolol
Answer: B) Isoniazid Explanation: Isoniazid is acetylated by N-acetyltransferase 2 (NAT2). "Slow acetylators" (more common in Caucasians/Egyptians) accumulate isoniazid, risking peripheral neuropathy. "Fast acetylators" (common in Japanese/Inuit) metabolize it rapidly, risking hepatotoxicity from reactive metabolite accumulation.

SECTION D: PHARMACOKINETICS - EXCRETION & CLEARANCE

Q23. Renal clearance of a drug equals the rate of urinary excretion divided by:
  • A) Total body clearance
  • B) Plasma drug concentration
  • C) Volume of distribution
  • D) Half-life
Answer: B) Plasma drug concentration Explanation: Clearance = Rate of elimination / Plasma concentration (C). Renal clearance specifically = Rate of urinary drug excretion / Plasma drug concentration. Units are mL/min or L/hr.
Q24. A drug that is freely filtered at the glomerulus, not secreted, but extensively reabsorbed in the tubules would have a renal clearance:
  • A) Equal to GFR (125 mL/min)
  • B) Greater than GFR
  • C) Less than GFR
  • D) Equal to total body clearance
Answer: C) Less than GFR Explanation: GFR ~125 mL/min for a drug freely filtered but not secreted/reabsorbed. Tubular reabsorption reduces the amount excreted, so clearance < GFR. Active tubular secretion would give clearance > GFR.
Q25. The elimination half-life (t1/2) of a drug following first-order kinetics is:
  • A) t1/2 = Vd / Cl
  • B) t1/2 = 0.693 × Vd / Cl
  • C) t1/2 = Cl / Vd
  • D) t1/2 = Dose / AUC
Answer: B) t1/2 = 0.693 × Vd / Cl Explanation: For first-order kinetics: t1/2 = 0.693 × (Vd / Cl). This shows that t1/2 is directly proportional to Vd and inversely proportional to clearance. Increasing Vd or decreasing Cl both prolong half-life.
Q26. In zero-order kinetics, the plasma drug concentration decreases at:
  • A) A rate proportional to the drug concentration
  • B) A constant amount per unit time (fixed rate)
  • C) An exponential rate
  • D) A rate proportional to the square of concentration
Answer: B) A constant amount per unit time (fixed rate) Explanation: Zero-order kinetics occurs when elimination mechanisms are saturated (e.g., ethanol, phenytoin at high doses, aspirin in overdose). The rate of elimination is constant (e.g., 10 mg/hr regardless of concentration) because the enzyme is already working at maximum capacity (Vmax).
Q27. Steady-state (Css) during continuous IV infusion is reached after approximately:
  • A) 1 half-life
  • B) 3 half-lives (90% of Css)
  • C) 4-5 half-lives (~94-97% of Css)
  • D) 10 half-lives
Answer: C) 4-5 half-lives (~94-97% of Css) Explanation: During constant IV infusion, steady-state is approached asymptotically. After 1 t1/2 = 50%, 2 t1/2 = 75%, 3 t1/2 = 87.5%, 4 t1/2 = 93.75%, 5 t1/2 = 96.9%. Clinically, 4-5 half-lives is accepted as steady-state.
Q28. A loading dose is used to:
  • A) Decrease clearance of a drug
  • B) Rapidly achieve therapeutic plasma levels for drugs with long half-lives
  • C) Prevent zero-order kinetics
  • D) Decrease Vd
Answer: B) Rapidly achieve therapeutic plasma levels for drugs with long half-lives Explanation: Loading dose = Vd × Target Css. Without a loading dose, a drug with a 24-hour t1/2 would take 4-5 days to reach steady-state. Examples: digoxin, amiodarone, vancomycin loading doses.
Q29. Hepatic clearance of a "high extraction ratio" drug (e.g., lidocaine, morphine) is primarily dependent on:
  • A) Plasma protein binding
  • B) Liver blood flow
  • C) Intrinsic hepatic enzyme activity
  • D) Glomerular filtration rate
Answer: B) Liver blood flow Explanation: High extraction ratio drugs (ER > 0.7) are efficiently removed by the liver on first pass. Their clearance approximates hepatic blood flow (~1500 mL/min). Reduced liver blood flow (heart failure, portal hypertension) dramatically reduces their clearance. Enzyme inhibitors have minimal effect on these drugs.
Q30. Enterohepatic cycling of a drug results in:
  • A) Decreased half-life and faster elimination
  • B) Prolonged half-life and extended drug action
  • C) Reduced bioavailability
  • D) Increased renal excretion
Answer: B) Prolonged half-life and extended drug action Explanation: Enterohepatic cycling occurs when conjugated drugs excreted in bile are hydrolyzed by intestinal bacteria, releasing free drug that is reabsorbed. This recirculation prolongs the drug's half-life and duration of action (e.g., oral contraceptives, morphine, digoxin).

SECTION E: COMPARTMENT MODELS

Q31. A one-compartment model assumes that:
  • A) The body consists of two distinct compartments with different drug concentrations
  • B) The drug distributes instantly and uniformly throughout the body
  • C) The drug distributes slowly between central and peripheral compartments
  • D) Only renal excretion occurs
Answer: B) The drug distributes instantly and uniformly throughout the body Explanation: In a one-compartment model, drug is assumed to instantaneously equilibrate throughout the body. After IV injection, a log-linear decline in plasma concentration is seen. This is the simplest model and applies to many water-soluble drugs confined to the ECF.
Q32. In a two-compartment model, the plasma concentration-time curve after IV bolus shows:
  • A) A straight line on semi-log plot
  • B) A bi-exponential decline with a rapid alpha phase and slow beta phase
  • C) A zero-order decline
  • D) A constant concentration
Answer: B) A bi-exponential decline with a rapid alpha phase and slow beta phase Explanation: The two-compartment model has a central compartment (blood, well-perfused organs) and a peripheral compartment (muscle, fat). After IV bolus, the alpha phase represents rapid distribution from central to peripheral compartment + elimination. The beta (terminal) phase represents slower elimination after equilibrium.
Q33. The "alpha phase" in a two-compartment PK model primarily represents:
  • A) Drug elimination by kidneys
  • B) Distribution from central to peripheral compartment
  • C) Absorption
  • D) Hepatic metabolism
Answer: B) Distribution from central to peripheral compartment Explanation: The alpha (distribution) phase is characterized by rapid fall in plasma concentration as drug moves from the central compartment (plasma, well-perfused tissues) to the peripheral compartment (muscle, fat, skin). During this phase, the drug is not yet at equilibrium.
Q34. Non-compartmental analysis (NCA) of pharmacokinetics is advantageous because:
  • A) It requires a pre-defined compartmental model
  • B) It is model-independent and uses AUC to estimate key PK parameters
  • C) It requires fewer data points
  • D) It can only analyze linear kinetics
Answer: B) It is model-independent and uses AUC to estimate key PK parameters Explanation: NCA calculates parameters like AUC, clearance (Cl = Dose/AUC), mean residence time (MRT), and Vd (Vss) directly from the observed data without assuming a specific compartmental structure. It is widely used in regulatory submissions.

SECTION F: PHARMACODYNAMICS - RECEPTORS & SIGNAL TRANSDUCTION

Q35. According to the occupation theory (Clark's theory), the pharmacological effect is:
  • A) Proportional to the rate of drug-receptor complex formation
  • B) Proportional to the fraction of receptors occupied by the drug
  • C) Independent of receptor occupancy
  • D) Determined only by receptor density
Answer: B) Proportional to the fraction of receptors occupied by the drug Explanation: Clark's occupation theory (1926) states that the magnitude of drug effect is directly proportional to the number of receptors occupied. Maximum effect (Emax) occurs when all receptors are occupied. This was later modified by Stephenson (efficacy concept) and Ariens (intrinsic activity).
Q36. The term "intrinsic activity" (alpha) as defined by Ariens refers to:
  • A) The ability of a drug to bind to a receptor
  • B) The capacity of a drug to produce a pharmacological response after receptor binding (0-1 scale)
  • C) The rate of drug-receptor dissociation
  • D) Drug selectivity for a receptor subtype
Answer: B) The capacity of a drug to produce a pharmacological response after receptor binding (0-1 scale) Explanation: Ariens defined intrinsic activity (α) as the maximum effect a drug can produce relative to a full agonist (α = 1). Full agonists have α = 1, partial agonists 0 < α < 1, and antagonists α = 0. It is distinct from affinity (ability to bind).
Q37. A partial agonist differs from a full agonist in that:
  • A) It has lower affinity for the receptor
  • B) It can never reach Emax even at full receptor occupancy
  • C) It has lower potency only
  • D) It has no clinical applications
Answer: B) It can never reach Emax even at full receptor occupancy Explanation: A partial agonist has intrinsic activity between 0 and 1 - it activates the receptor but cannot produce the maximum response a full agonist can. Buprenorphine (partial mu-opioid agonist) and pindolol (partial beta-blocker agonist) are clinical examples.
Q38. An inverse agonist:
  • A) Produces no effect on its own but blocks agonist effects
  • B) Binds to the receptor and produces an effect opposite to the agonist (negative intrinsic activity)
  • C) Increases constitutive receptor activity
  • D) Is identical to a competitive antagonist
Answer: B) Binds to the receptor and produces an effect opposite to the agonist (negative intrinsic activity) Explanation: Many receptors show constitutive (basal) activity in the absence of ligand. An inverse agonist binds to the receptor and reduces activity below the basal level. Example: certain beta-carboline compounds at benzodiazepine receptors produce anxiogenic effects (opposite to diazepam).
Q39. G-protein coupled receptors (GPCRs) belong to which receptor superfamily?
  • A) Ligand-gated ion channels (ionotropic)
  • B) Transmembrane receptors with intrinsic tyrosine kinase
  • C) 7-transmembrane (heptahelical) receptors linked to G proteins
  • D) Intracellular nuclear receptors
Answer: C) 7-transmembrane (heptahelical) receptors linked to G proteins Explanation: GPCRs have 7 alpha-helical transmembrane segments, an extracellular N-terminus, and intracellular C-terminus. Examples: adrenergic, muscarinic, dopaminergic, histamine H1/H2, opioid, serotonin (5HT1/2) receptors. They are the largest druggable receptor superfamily.
Q40. Beta-adrenergic receptors activate which G protein subtype?
  • A) Gi (inhibitory) - decreases cAMP
  • B) Gq - activates phospholipase C
  • C) Gs (stimulatory) - activates adenylyl cyclase, increases cAMP
  • D) G12/13 - activates Rho GTPase
Answer: C) Gs (stimulatory) - activates adenylyl cyclase, increases cAMP Explanation: Beta-adrenoceptors (beta-1, beta-2, beta-3) couple to Gs protein. Agonist binding → Gs activation → adenylyl cyclase activation → increased cAMP → PKA activation → downstream phosphorylation (e.g., cardiac inotropy for beta-1, smooth muscle relaxation for beta-2).
Q41. Alpha-2 adrenoceptors inhibit norepinephrine release via:
  • A) Gs protein - increased cAMP
  • B) Gq protein - IP3/DAG second messengers
  • C) Gi protein - inhibition of adenylyl cyclase, decreased cAMP
  • D) Ion channel activation
Answer: C) Gi protein - inhibition of adenylyl cyclase, decreased cAMP Explanation: Alpha-2 adrenoceptors couple to Gi protein. Activation (by clonidine, methyldopa) inhibits adenylyl cyclase, decreasing cAMP. As prejunctional autoreceptors, they reduce NE release, explaining the anti-hypertensive effect of clonidine.
Q42. The second messenger for M1/M3 muscarinic and H1 histamine receptors is:
  • A) cAMP via Gs protein
  • B) IP3 and DAG via Gq-PLC pathway
  • C) cGMP via guanylyl cyclase
  • D) Decreased cAMP via Gi protein
Answer: B) IP3 and DAG via Gq-PLC pathway Explanation: M1, M3, H1, Alpha-1 adrenoceptors couple to Gq. Gq activates phospholipase C-beta → cleaves PIP2 into IP3 + DAG. IP3 releases Ca2+ from ER, and DAG activates PKC. This pathway mediates smooth muscle contraction, glandular secretion, etc.
Q43. Inositol 1,4,5-trisphosphate (IP3) acts on which intracellular target?
  • A) Adenylyl cyclase
  • B) Protein kinase A
  • C) IP3-gated Ca2+ channels on the endoplasmic reticulum
  • D) Mitochondrial respiratory chain
Answer: C) IP3-gated Ca2+ channels on the endoplasmic reticulum Explanation: IP3 binds to IP3R receptors (calcium release channels) on the endoplasmic/sarcoplasmic reticulum, triggering release of stored Ca2+ into the cytoplasm. The resulting Ca2+ rise activates calmodulin-dependent kinases, smooth muscle contraction, and secretion (Katzung, 16th ed).
Q44. Sildenafil (Viagra) exerts its vasodilating effect by:
  • A) Activating guanylyl cyclase directly
  • B) Inhibiting phosphodiesterase-5 (PDE5), preventing cGMP degradation
  • C) Blocking alpha-1 adrenoceptors
  • D) Activating Gs protein
Answer: B) Inhibiting phosphodiesterase-5 (PDE5), preventing cGMP degradation Explanation: NO released from endothelium activates soluble guanylyl cyclase → cGMP → PKG → myosin dephosphorylation → smooth muscle relaxation. Sildenafil inhibits PDE5 (which degrades cGMP), thus amplifying and prolonging the cGMP signal in penile and pulmonary vasculature (Katzung).
Q45. Receptor tyrosine kinases (RTKs) are activated by:
  • A) G proteins
  • B) Steroid hormones
  • C) Peptide hormones and growth factors (e.g., insulin, EGF, PDGF)
  • D) Nitric oxide
Answer: C) Peptide hormones and growth factors (e.g., insulin, EGF, PDGF) Explanation: RTKs (e.g., insulin receptor, EGFR, HER2) have extracellular ligand-binding domains and intracellular tyrosine kinase domains. Ligand binding causes receptor dimerization → autophosphorylation of tyrosine residues → activation of downstream signaling cascades (RAS-MAPK, PI3K-AKT).
Q46. Intracellular (nuclear) receptors are activated by:
  • A) Catecholamines
  • B) Lipophilic molecules: steroids, thyroid hormones, vitamin D, retinoids
  • C) Peptide hormones
  • D) Neurotransmitters
Answer: B) Lipophilic molecules: steroids, thyroid hormones, vitamin D, retinoids Explanation: Nuclear receptors (e.g., glucocorticoid, estrogen, androgen, thyroid hormone receptors) reside in the cytoplasm or nucleus. Lipophilic ligands diffuse through the cell membrane, bind to these receptors, causing receptor-DNA binding (HRE - hormone response elements) → gene transcription changes. Onset is slow (hours).
Q47. Ligand-gated ion channels (ionotropic receptors) are characterized by:
  • A) Slow onset of action (hours) via gene transcription
  • B) Fastest onset of action (milliseconds) via direct ion flow
  • C) Signaling via second messengers
  • D) 7-transmembrane structure
Answer: B) Fastest onset of action (milliseconds) via direct ion flow Explanation: Ionotropic receptors (nAChR, GABA-A, NMDA, AMPA, 5HT3 receptors) are ligand-gated ion channels. Ligand binding directly opens the channel within milliseconds without a second messenger. They mediate fast synaptic transmission in the CNS and neuromuscular junction.

SECTION G: DOSE-RESPONSE RELATIONSHIPS

Q48. EC50 (or ED50) in a graded dose-response curve represents:
  • A) The maximum effect a drug can produce
  • B) The dose/concentration that produces 50% of the maximal response
  • C) The dose required to produce toxicity in 50% of animals
  • D) The plasma protein binding affinity
Answer: B) The dose/concentration that produces 50% of the maximal response Explanation: EC50 is a measure of drug potency. A drug with a lower EC50 is more potent (requires less drug for half-maximal effect). It is distinct from Emax (efficacy). Two drugs can have the same Emax but very different EC50 values.
Q49. Emax in a dose-response curve represents:
  • A) The dose at which 50% of the population responds
  • B) The maximum effect a drug can produce regardless of dose
  • C) The drug's affinity for its receptor
  • D) The therapeutic index
Answer: B) The maximum effect a drug can produce regardless of dose Explanation: Emax is a measure of a drug's efficacy (intrinsic activity). It represents the ceiling effect - increasing the dose above that which saturates all receptors produces no further effect. High-efficacy drugs produce greater Emax than low-efficacy drugs.
Q50. Competitive antagonism shifts the agonist dose-response curve:
  • A) Upward (increases Emax), no change in EC50
  • B) To the right (increases EC50), no change in Emax
  • C) Downward (decreases Emax), no change in EC50
  • D) To the left (decreases EC50), no change in Emax
Answer: B) To the right (increases EC50), no change in Emax Explanation: A competitive antagonist competes reversibly with the agonist at the same binding site. Adding more agonist can displace the antagonist (surmountable antagonism). This shifts the curve rightward (higher EC50 = less potent) but Emax is unchanged because all receptors can still be activated by sufficient agonist.
Q51. Non-competitive (irreversible) antagonism produces which change in the dose-response curve?
  • A) Right shift only, Emax unchanged
  • B) Left shift, Emax unchanged
  • C) Downward shift (decreased Emax), little or no EC50 change
  • D) Increased Emax with right shift
Answer: C) Downward shift (decreased Emax), little or no EC50 change Explanation: Non-competitive antagonists (irreversible/allosteric) reduce the total number of available receptors or prevent receptor activation. Maximum agonist response decreases (lower Emax) because even saturating agonist concentrations cannot overcome the blockade. EC50 may be unchanged or slightly increased (Lippincott).
Q52. The therapeutic index (TI) of a drug is calculated as:
  • A) ED50 / LD50
  • B) LD50 / ED50
  • C) EC50 × Emax
  • D) Vd × Cl
Answer: B) LD50 / ED50 Explanation: TI = LD50/ED50 (in animal studies) or TD50/ED50 in humans. A higher TI indicates a safer drug (wider margin between effective and toxic dose). Drugs with narrow TI (e.g., digoxin, warfarin, lithium, phenytoin) require careful monitoring.
Q53. Which of the following represents a quantal dose-response relationship?
  • A) Graded increase in blood pressure with increasing dose of norepinephrine
  • B) All-or-nothing response: drug either prevents convulsions or does not in an individual
  • C) Continuous increase in heart rate with increasing isoproterenol
  • D) Progressive muscle relaxation with increasing d-tubocurarine
Answer: B) All-or-nothing response: drug either prevents convulsions or does not in an individual Explanation: Quantal (all-or-none) dose-response relationships measure the proportion of a population that shows a defined response (e.g., prevention of seizures, loss of consciousness). They are used to derive ED50, LD50, and the therapeutic index.
Q54. "Spare receptors" (receptor reserve) means that:
  • A) Receptors are present in excess - Emax is achieved before all receptors are occupied
  • B) All receptors must be occupied for maximum effect
  • C) Extra receptors are produced only after drug exposure
  • D) Spare receptors are inactive
Answer: A) Receptors are present in excess - Emax is achieved before all receptors are occupied Explanation: Spare receptors allow maximum effect at low agonist concentrations (low EC50) even though total receptor occupancy is <100% (proposed by Stephenson). They explain why even significant receptor blockade (e.g., 90% by an irreversible antagonist) may not reduce Emax if sufficient spare receptors remain.

SECTION H: AGONISTS, ANTAGONISTS & RECEPTOR REGULATION

Q55. Which of the following is an example of a competitive reversible antagonist?
  • A) Phenoxybenzamine at alpha receptors
  • B) Aspirin's irreversible COX inhibition
  • C) Naloxone at opioid receptors
  • D) Organophosphate inhibition of AChE
Answer: C) Naloxone at opioid receptors Explanation: Naloxone is a pure competitive reversible antagonist at all opioid receptor subtypes (mu, kappa, delta). Its effects can be overcome by increasing opioid dose, and the block is reversed over time as naloxone dissociates. Phenoxybenzamine alkylates alpha receptors irreversibly.
Q56. The clinical consequence of receptor downregulation (desensitization) seen with prolonged beta-agonist use in asthma is:
  • A) Increased sensitivity to the drug
  • B) Tachyphylaxis/tolerance - reduced response over time
  • C) Permanent receptor deletion
  • D) Enhanced second-messenger signaling
Answer: B) Tachyphylaxis/tolerance - reduced response over time Explanation: Prolonged agonist stimulation leads to receptor desensitization via: (1) receptor phosphorylation (GRK), (2) internalization/sequestration, and (3) downregulation (reduced receptor synthesis). This reduces bronchodilator efficacy (tolerance) seen with chronic LABA use in asthma.
Q57. Receptor upregulation (supersensitivity) is seen after:
  • A) Prolonged agonist administration
  • B) Prolonged antagonist treatment - abrupt withdrawal leads to exaggerated response
  • C) Acute drug overdose
  • D) CYP enzyme induction
Answer: B) Prolonged antagonist treatment - abrupt withdrawal leads to exaggerated response Explanation: Prolonged blockade by antagonists leads to compensatory upregulation (increased receptor density). Abrupt withdrawal unmasks supersensitivity. Classic example: abrupt propranolol (beta-blocker) withdrawal causing rebound tachycardia and angina. Clonidine withdrawal causing hypertensive crisis.
Q58. Tachyphylaxis differs from drug tolerance in that:
  • A) Tachyphylaxis develops slowly over weeks
  • B) Tachyphylaxis develops rapidly after a few doses, often due to receptor desensitization or depletion of mediator
  • C) Tolerance is receptor-mediated only
  • D) They are identical terms
Answer: B) Tachyphylaxis develops rapidly after a few doses, often due to receptor desensitization or depletion of mediator Explanation: Tachyphylaxis is rapid onset tolerance occurring within minutes to hours (e.g., ephedrine loses its sympathomimetic effect with repeated doses due to NE depletion). Drug tolerance develops over days to weeks through various mechanisms including receptor desensitization, pharmacokinetic changes, and homeostatic counter-regulation.
Q59. In the Langmuir adsorption equation applied to drug-receptor binding, if [D] = KD, then receptor occupancy is:
  • A) 0%
  • B) 25%
  • C) 50%
  • D) 100%
Answer: C) 50% Explanation: Receptor occupancy = [D] / ([D] + KD). When [D] = KD: occupancy = KD / (KD + KD) = 1/2 = 50%. Therefore, KD (equilibrium dissociation constant) is the drug concentration that occupies 50% of receptors. Lower KD = higher affinity.
Q60. The pA2 value (Schild equation) is used to measure:
  • A) Agonist potency
  • B) Antagonist potency - the negative log of the antagonist concentration that shifts agonist EC50 twofold
  • C) Drug bioavailability
  • D) Volume of distribution
Answer: B) Antagonist potency - the negative log of the antagonist concentration that shifts agonist EC50 twofold Explanation: The Schild equation (Arunlakshana & Schild): log(DR-1) = log[B] - log KB, where DR = dose ratio (EC50 with antagonist / EC50 without). pA2 = -log KB (antagonist equilibrium dissociation constant). Higher pA2 = greater antagonist potency.

SECTION I: ION CHANNELS & ENZYME TARGETS

Q61. Voltage-gated Na+ channels are the primary target of which class of drugs?
  • A) ACE inhibitors
  • B) Local anesthetics (lidocaine) and Class I antiarrhythmics
  • C) Calcium channel blockers (verapamil)
  • D) Proton pump inhibitors
Answer: B) Local anesthetics (lidocaine) and Class I antiarrhythmics Explanation: Voltage-gated Na+ channels (Nav1.1-1.9) are blocked by local anesthetics (lidocaine, bupivacaine) which prevent neuronal action potentials, and Class I antiarrhythmics (quinidine, flecainide) which slow cardiac conduction. They bind the inactivated state preferentially (use-dependent block).
Q62. ATP-sensitive K+ channels (KATP) in pancreatic beta cells are blocked by:
  • A) Diazoxide (opens KATP)
  • B) Sulfonylureas (glibenclamide, glipizide) - block KATP, causing insulin release
  • C) Potassium-sparing diuretics
  • D) Minoxidil
Answer: B) Sulfonylureas (glibenclamide, glipizide) - block KATP, causing insulin release Explanation: In pancreatic beta cells, glucose metabolism → ATP ↑ → KATP closes → membrane depolarization → voltage-gated Ca2+ channels open → insulin exocytosis. Sulfonylureas mimic this by blocking KATP directly, independent of glucose levels (risk of hypoglycemia in fasting).
Q63. Drugs that inhibit enzymes as their primary mechanism include all of the following EXCEPT:
  • A) Aspirin (inhibits COX)
  • B) Captopril (inhibits ACE)
  • C) Allopurinol (inhibits xanthine oxidase)
  • D) Digoxin (inhibits Na+/K+ ATPase)
Answer: D) Digoxin (inhibits Na+/K+ ATPase) Wait - Digoxin DOES inhibit Na+/K+ ATPase (an enzyme). All four options are enzyme inhibitors. Let me rephrase:
The drug whose primary mechanism does NOT involve enzyme inhibition is:
  • A) Methotrexate
  • B) Losartan
  • C) Neostigmine
  • D) Omeprazole
Answer: B) Losartan Explanation: Losartan is an AT1 receptor antagonist (ARB) - it blocks the angiotensin II receptor, not an enzyme. Methotrexate inhibits DHFR, neostigmine inhibits AChE, and omeprazole irreversibly inhibits H+/K+ ATPase (proton pump).
Q64. Irreversible inhibition of COX-1 by aspirin leads to permanent platelet dysfunction because:
  • A) Aspirin has a long plasma half-life
  • B) Platelets lack nuclei and cannot synthesize new COX enzyme
  • C) COX-1 is upregulated after aspirin use
  • D) Aspirin is not metabolized
Answer: B) Platelets lack nuclei and cannot synthesize new COX enzyme Explanation: Aspirin acetylates COX-1 irreversibly, permanently blocking TXA2 synthesis in platelets. Because anucleate platelets cannot synthesize new protein, the effect lasts the platelet lifespan (~7-10 days). This is the basis of aspirin's antiplatelet effect. Nucleated cells (endothelium, stomach) recover in hours.

SECTION J: SPECIAL PHARMACOKINETIC TOPICS

Q65. The Michaelis-Menten equation describes enzyme kinetics. At substrate concentrations far below Km, drug elimination follows:
  • A) Zero-order kinetics
  • B) First-order kinetics (rate proportional to concentration)
  • C) Second-order kinetics
  • D) Non-linear kinetics
Answer: B) First-order kinetics Explanation: Michaelis-Menten: v = Vmax × [S] / (Km + [S]). When [S] << Km: v ≈ Vmax × [S] / Km = k × [S] (first-order). When [S] >> Km: v ≈ Vmax (zero-order, enzyme saturated). Phenytoin exhibits mixed kinetics - first-order at low doses, zero-order at therapeutic doses.
Q66. Area Under the Curve (AUC) represents:
  • A) Volume of distribution
  • B) Total drug exposure of the body over time
  • C) Rate of absorption
  • D) Elimination rate constant
Answer: B) Total drug exposure of the body over time Explanation: AUC (mg·h/L) is calculated by the trapezoidal rule. It reflects total systemic drug exposure. It is used to: (1) calculate absolute bioavailability, (2) determine clearance (Cl = Dose/AUC for IV), and (3) compare bioequivalence between formulations.
Q67. Mean Residence Time (MRT) is related to half-life as:
  • A) MRT = t1/2
  • B) MRT = t1/2 / 0.693
  • C) MRT = 0.693 × t1/2
  • D) MRT = t1/2 × Vd
Answer: B) MRT = t1/2 / 0.693 = 1.44 × t1/2 Explanation: MRT is the statistical mean time for drug molecules to reside in the body. For a one-compartment model: MRT = 1/kel = t1/2/0.693. MRT is used in non-compartmental analysis and is conceptually equivalent to "average drug residence time."
Q68. Chinchona alkaloid quinidine's cardiac toxicity is potentiated by:
  • A) Decreased plasma pH (acidosis)
  • B) Hypokalemia (low serum potassium)
  • C) Elevated serum potassium
  • D) Increased Vd
Answer: B) Hypokalemia Explanation: Quinidine blocks cardiac Na+ and K+ channels. Hypokalemia potentiates QT prolongation by quinidine (quinidine syncope/torsades de pointes). Concurrent hypokalemia (from diuretics) is a major risk factor for drug-induced arrhythmias.
Q69. Which of the following parameters is most directly related to the duration of drug action after a single dose?
  • A) Bioavailability (F)
  • B) Elimination half-life (t1/2)
  • C) Peak plasma concentration (Cmax)
  • D) Time to peak (Tmax)
Answer: B) Elimination half-life (t1/2) Explanation: After a single dose, drug effect persists while drug concentration exceeds the minimum effective concentration. This duration depends on how fast the drug is eliminated - i.e., t1/2. A longer t1/2 means prolonged duration of action. Cmax determines peak intensity, Tmax determines time of peak effect.
Q70. Drug accumulation during repeated dosing is clinically significant when the dosing interval is:
  • A) Longer than 5 half-lives
  • B) Equal to 5 half-lives
  • C) Much shorter than the half-life
  • D) Equal to the half-life (moderate accumulation)
Answer: C) Much shorter than the half-life Explanation: When drugs are dosed at intervals much shorter than t1/2, significant accumulation occurs because insufficient elimination occurs between doses. Significant accumulation factor = 1 / (1 - e^(-kel × τ)). If dosing interval = t1/2, approximately 2-fold accumulation occurs at steady-state.

SECTION K: HIGH-YIELD ADVANCED & TRICKY QUESTIONS

Q71. A drug has a pKa of 8.4. At physiological pH (7.4), what percentage of a weak base is ionized?
  • A) 10%
  • B) 91%
  • C) 50%
  • D) 9%
Answer: B) 91% Explanation: For a weak base: [BH+]/[B] = 10^(pKa - pH) = 10^(8.4-7.4) = 10^1 = 10. So [ionized]/[unionized] = 10, meaning 10/11 = 91% is ionized (protonated = BH+) at pH 7.4. In acidic urine, weakly basic drugs are more ionized and less reabsorbed (used in amphetamine poisoning - acidify urine).
Q72. The "ceiling effect" of partial agonists is exploited in which clinical scenario?
  • A) Treatment of acute pain with maximum morphine doses
  • B) Buprenorphine in opioid substitution therapy - ceiling on respiratory depression reduces overdose risk
  • C) Maximum dose of beta-2 agonists in asthma
  • D) Benzodiazepine overdose
Answer: B) Buprenorphine in opioid substitution therapy Explanation: Buprenorphine (partial mu-opioid agonist, kappa antagonist) has a ceiling on respiratory depression and euphoria due to its partial agonism. This makes it safer in overdose than full agonists. However, in opioid-naive patients, it still provides sufficient analgesia for substitution therapy.
Q73. Phenytoin displays non-linear (Michaelis-Menten) pharmacokinetics because:
  • A) It undergoes extensive renal secretion
  • B) Hepatic CYP2C9 becomes saturated at therapeutic doses, shifting from first- to zero-order kinetics
  • C) It has a very small Vd
  • D) It is a prodrug
Answer: B) Hepatic CYP2C9 becomes saturated at therapeutic doses Explanation: Phenytoin's elimination switches from first-order to zero-order kinetics (saturable Michaelis-Menten) at therapeutic doses. This has critical clinical implications: small increases in dose cause disproportionately large increases in plasma concentration, making dose titration difficult and toxicity unpredictable.
Q74. The "flip-flop" pharmacokinetics phenomenon occurs when:
  • A) Drug distribution is faster than elimination
  • B) Absorption rate is slower than elimination rate - terminal slope reflects absorption, not elimination
  • C) Drug undergoes enterohepatic recycling
  • D) Vd exceeds plasma volume
Answer: B) Absorption rate is slower than elimination rate - terminal slope reflects absorption, not elimination Explanation: Normally, the terminal slope of a plasma concentration-time curve after oral dosing reflects elimination. In "flip-flop" kinetics (slow-release formulations, drugs with very fast elimination), the terminal slope reflects the slow absorption rate rather than elimination. This is important for interpreting extended-release drug PK profiles.
Q75. The Biopharmaceutics Classification System (BCS) Class II drugs are characterized by:
  • A) High solubility, high permeability
  • B) Low solubility, high permeability - dissolution is the rate-limiting step
  • C) High solubility, low permeability
  • D) Low solubility, low permeability
Answer: B) Low solubility, high permeability Explanation: BCS Classification: Class I (high sol, high perm - e.g., metoprolol), Class II (low sol, high perm - e.g., ibuprofen, griseofulvin, carbamazepine), Class III (high sol, low perm - e.g., atenolol), Class IV (low sol, low perm - e.g., hydrochlorothiazide). Class II drugs benefit from formulation strategies to enhance dissolution.
Q76. Physiologically Based Pharmacokinetic (PBPK) modeling is advantageous over classical compartmental modeling because:
  • A) It is simpler and requires fewer parameters
  • B) It uses actual physiological parameters (organ volumes, blood flows) and can extrapolate across species and populations
  • C) It eliminates the need for clinical pharmacokinetic studies
  • D) It only applies to IV administration
Answer: B) It uses actual physiological parameters and can extrapolate across species and populations Explanation: PBPK models incorporate organ blood flows, tissue volumes, partition coefficients, and enzyme kinetics. They can: (1) predict drug behavior in special populations (pediatrics, renal/hepatic impairment), (2) support inter-species extrapolation, (3) predict drug-drug interactions, and (4) guide drug development and regulatory submissions.
Q77. The term "pharmacogenomics" in the context of pharmacokinetics refers to:
  • A) Study of drug-induced mutations
  • B) Genetic variation in drug-metabolizing enzymes and transporters affecting individual PK profiles
  • C) Development of new drugs based on genomic targets
  • D) The use of pharmacokinetics in genome sequencing
Answer: B) Genetic variation in drug-metabolizing enzymes and transporters affecting individual PK profiles Explanation: Pharmacogenomics studies how genetic polymorphisms (SNPs) in CYP2D6, CYP2C19, CYP2C9, UGT enzymes, P-gp (ABCB1), and other genes alter drug metabolism and transport. Examples: CYP2D6 in codeine/tamoxifen, CYP2C19 in clopidogrel activation, CYP2C9+VKORC1 in warfarin dosing.
Q78. Which of the following correctly describes the difference between potency and efficacy?
  • A) Potency = Emax; Efficacy = EC50
  • B) Potency reflects EC50 (lower EC50 = more potent); Efficacy reflects Emax (higher Emax = more efficacious)
  • C) Potency and efficacy are interchangeable terms
  • D) A drug can have high potency only if it also has high efficacy
Answer: B) Potency = EC50; Efficacy = Emax Explanation: Potency is the concentration required to achieve half-maximum effect - a more potent drug needs less to achieve an effect. Efficacy (intrinsic activity) is the maximum effect achievable. A drug can be highly potent (low EC50) but have low efficacy (partial agonist with low Emax). Clinical example: buprenorphine is potent but less efficacious than morphine.
Q79. The Emax model equation for a graded dose-response relationship is:
  • A) E = Emax × [D] / [D] + EC50
  • B) E = EC50 × [D]
  • C) E = Emax - EC50 × [D]
  • D) E = Emax / [D]
Answer: A) E = Emax × [D] / ([D] + EC50) Explanation: The Hill equation (sigmoid Emax model): E = Emax × [D]^n / (EC50^n + [D]^n), where n is the Hill coefficient (cooperativity). When n=1, this simplifies to E = Emax × [D] / ([D] + EC50). At [D] = EC50, E = Emax/2 (50% max effect). This equation describes most graded dose-response curves.
Q80. A new drug shows 80% receptor occupancy but only 40% of maximum response. This suggests:
  • A) The drug is a full agonist
  • B) The drug has spare receptors only
  • C) The drug has partial agonist activity (low intrinsic activity)
  • D) The assay is incorrect
Answer: C) The drug has partial agonist activity (low intrinsic activity) Explanation: A full agonist with spare receptors would show maximum response at <100% occupancy. Here, even at 80% occupancy, only 40% Emax is achieved - indicating the drug has low intrinsic activity (partial agonist, α < 1). The receptor is occupied but the activation efficacy per receptor is low.

SECTION L: RECEPTOR CLASSIFICATION QUICK-FIRE

Q81. Nicotinic acetylcholine receptor belongs to which receptor superfamily?
  • A) GPCR (7-TM)
  • B) Ligand-gated ion channel (ionotropic)
  • C) Receptor tyrosine kinase
  • D) Nuclear receptor
Answer: B) Ligand-gated ion channel (ionotropic) Explanation: Nicotinic AChR (nAChR) is a pentameric ligand-gated Na+/K+ ion channel. Two ACh molecules bind cooperatively to open the channel, producing rapid depolarization. Found at NMJ (N2/NM subtype) and autonomic ganglia (N1/NN subtype).
Q82. GABA-A receptor is a:
  • A) GPCR coupled to Gi
  • B) Ligand-gated Cl- channel
  • C) Ligand-gated Ca2+ channel
  • D) Nuclear receptor
Answer: B) Ligand-gated Cl- channel Explanation: GABA-A receptor is a pentameric ionotropic receptor. GABA binding opens a Cl- channel, causing hyperpolarization (inhibition). Benzodiazepines bind at the alpha-gamma subunit interface to enhance GABA's effect (positive allosteric modulation). Barbiturates and anesthetic steroids also modulate it.
Q83. The receptor for insulin is:
  • A) GPCR
  • B) Ligand-gated ion channel
  • C) Receptor tyrosine kinase (heterotetrameric alpha-2 beta-2 structure)
  • D) Cytokine receptor
Answer: C) Receptor tyrosine kinase Explanation: The insulin receptor is a heterotetrameric RTK (2 alpha + 2 beta subunits linked by disulfide bonds). Insulin binds to alpha subunits → conformational change → beta subunit tyrosine autophosphorylation → IRS-1 phosphorylation → PI3K/AKT (metabolic effects) and RAS/MAPK (growth effects) pathways.
Q84. Which receptor type has the SLOWEST onset of action?
  • A) Ligand-gated ion channel (nAChR)
  • B) GPCR (adrenergic receptor)
  • C) RTK (insulin receptor)
  • D) Nuclear/intracellular receptor (steroid hormone receptor)
Answer: D) Nuclear/intracellular receptor (steroid hormone receptor) Explanation: Onset of action by receptor type: Ion channels (ms) < GPCRs (sec-min) < RTKs/enzyme-linked (min-hours) < Nuclear receptors (hours-days, due to gene transcription and new protein synthesis). Corticosteroid anti-inflammatory effects take 6-12 hours minimum.
Q85. Calcitonin gene-related peptide (CGRP) receptor antagonists (gepants) work by blocking:
  • A) Na+ channels
  • B) Class B1 GPCR (calcitonin receptor-like receptor/RAMP1 complex)
  • C) RTK signaling
  • D) COX-2 enzyme
Answer: B) Class B1 GPCR (CGRP receptor - CLR/RAMP1 complex) Explanation: CGRP receptors are heterodimeric GPCRs formed by CLR (calcitonin receptor-like receptor) + RAMP1 (receptor activity-modifying protein 1). They couple to Gs → cAMP elevation → vasodilation. Gepants (rimegepant, ubrogepant) are competitive CGRP receptor antagonists used for migraine.

SUMMARY TABLE: Key PK Parameters

ParameterFormulaClinical Significance
Bioavailability (F)AUC(oral)/AUC(IV) × 100Fraction absorbed unchanged
VdDose/C0 or Amount/CpExtent of tissue distribution
Clearance (Cl)Dose/AUC or Vd × kelRate of elimination
t1/20.693 × Vd/ClDuration of action, dosing interval
EC50From dose-response curvePotency measure
EmaxMaximum effectEfficacy measure
TILD50/ED50Safety margin
CssDose rate/ClSteady-state concentration
Loading doseVd × Target CssRapid therapeutic level

SUMMARY TABLE: Receptor Types

Receptor ClassMechanismOnsetExamples
Ionotropic (LGIC)Ion channelMillisecondsnAChR, GABA-A, NMDA, AMPA, 5HT3
GPCR (7-TM)G protein → 2nd messengerSeconds-minAdrenergic, Muscarinic, Opioid, Dopamine
RTKTyrosine kinase → gene effectsMin-hoursInsulin, EGF, PDGF, IGF-1
NuclearGene transcriptionHours-daysSteroids, Thyroid hormone, Vit D, Retinoids
Sources: Lippincott Illustrated Reviews: Pharmacology (9781975170561) | Katzung's Basic & Clinical Pharmacology 16e (9781260463309) | Goodman & Gilman's Pharmacological Basis of Therapeutics (9781264258079)
This bank of 85 MCQs covers every high-yield topic in M.Pharm Sem 1 Advanced Pharmacology Unit 1:
  • Pharmacokinetics: ADME, Vd, clearance, t1/2, compartment models, zero/first-order kinetics, PK parameters
  • Pharmacodynamics: receptor types, signal transduction (cAMP, IP3/DAG, cGMP, RTK, nuclear), agonist/antagonist pharmacology, dose-response curves, TI, spare receptors, desensitization
  • Advanced topics: BCS classification, PBPK, pharmacogenomics, Schild equation, pA2, flip-flop kinetics
This is a shared conversation. Sign in to Orris to start your own chat.